期刊文献+

HPLC-MS/MS法测定白消安的血药浓度 被引量:3

Determination of Busulfan plasma drug concentration by HPLC-MS/MS
暂未订购
导出
摘要 目的建立测定白消安血药浓度的HPLC-MS/MS分析方法。方法血浆中加入白消安-d8作为内标,以乙腈提取,进行HPLC-MS/MS的测定。采用Agilent ZORBA SB-C18色谱柱(150mm×4.6mm,5μm),以10mmol·L^-1乙酸铵缓冲液∶甲醇(60∶40)作为流动相,流速:0.5m L·min^-1,柱温:35℃,进样量:10μL;质谱条件:采用电喷雾离子源(ESI)四级杆质谱,以选择性离子监测方式(SIM)进行正离子检测。结果白消安的线性范围为0.0206~10.2826μmol·L^-1,标准曲线为y=1.148x+5.400×10-2,r=0.9980,低、中、高3个浓度质控样品日内和日间RSD均〈15%,平均提取回收率为94.26%。结论该方法准确、灵敏、快速,已成功应用于白消安血药浓度的测定及其体内药动学分析。 OBJECTIVE To established an analysis method to determine Busulfan plasma concentration by liquid chromatography-tandem mass spectrometry(HPLC-MS/MS). METHODS Busulfan in human plasma was extracted by 1acetonitrle,with Busulfan-d8 as internal standard. The samples were separated by Agilent ZORBA SB-C18column(150 mm × 4. 6mm,5μm),the mobile phase consisted of 10 mmol · L^-1ammonium acetate ∶ methanol(60 ∶40),as flow rate of 0. 5m L·min^-1,column temperature: 35℃,injection volume: 10μL. Mass spectrometry conditions:triple-quadrupole mass spectrometry with electrospray ion source,positive ion detection in selective ion monitoring mode. RESULTS The linear range of busulfan was 0. 0206- 10. 2826μmol · L^-1,the standard curve is Y =0. 008 X + 0. 011,r = 0. 96,the intra-and inter-day RSDs were all below 15% at low,moderate and high concentrations. The mean extract recoveries were 94. 26%. CONCLUSION The method is accurate,sensitive,fast,and is suitable for the determination of Busulfan plasma drug concentration and its pharmacokinetic analysis.
出处 《海峡药学》 2014年第11期243-246,共4页 Strait Pharmaceutical Journal
基金 福建省战略新兴技术应用项目(2013J01371)
关键词 白消安 血药浓度 高效液相-质谱联用法 Busulfan Plasma concentrations HPLC-MS/MS
  • 相关文献

参考文献8

二级参考文献40

  • 1孙自敏,王祖贻,刘会兰,刘欣,朱薇波,韩永胜,杨会志,潘理明,吴树农,吴竟生.异基因造血干细胞移植治疗恶性血液病[J].临床血液学杂志,2004,17(5):257-260. 被引量:5
  • 2张善堂,方焱,屈建,陈象青,沈爱宗,孙言才.柱前衍生高效液相色谱法测定人血浆中白消安的浓度[J].中国医院药学杂志,2007,27(4):458-461. 被引量:16
  • 3陈新谦 金有豫.新编药物学(第十三版)[M].北京:人民卫生出版社,1993.181.
  • 4Anderson BS, Kashyap A, Gian V, et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (Ⅳ BuCy2 ) for hematologic malignancies prior to allogeneic stem cell transplantation: Aphase Ⅱ study. Biol Blood Marrow Transplantation, 2002, 8 (3): 145-154.
  • 5Hassan M, Ljungrnan P, Bolme P, et al. Busulfan bioavail - ability. Blood, 1994, 84:2144-2150.
  • 6Kashyap A, Wingard J, Cagnoni P, et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venocclusive disease (HVOD), HVOD -related mortality, and overall 100- day mortality. Biol Blood Marrow Transplantation, 2002, 8 (9): 493-500.
  • 7Hassan M, Nilsson C, Hassan Z, et al. Bone Marrow Transplantation, 2002, 30 : 833.
  • 8Vassal G, Koscielnv S, Challine D, et al. Busulfan dispositionand hepatic veno- occlusive disease in children undergoing bone marrow transplantation. Cancer Chemother Pharmacol, 1996, 37 (3) : 247 - 253.
  • 9Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transpIantation induction regimens. Semin Oncol, 1993, 20 (4) : 18 -25.
  • 10Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone transplantation. Cancer Chemother Pharmacol, 1989, 25 (1): 55-61.

共引文献25

同被引文献22

  • 1王玲玲,宗国军,高嵩,胡应和.柱前衍生高效液相色谱法测定注射液中白消安的研究[J].分析试验室,2006,25(6):18-20. 被引量:3
  • 2张善堂,方焱,屈建,陈象青,沈爱宗,孙言才.柱前衍生高效液相色谱法测定人血浆中白消安的浓度[J].中国医院药学杂志,2007,27(4):458-461. 被引量:16
  • 3童秀珍,许多荣,邹外一,李娟,罗绍凯,彭爱华,张国材,郑冬.静脉剂型白消安为主的预处理方案对接受异基因造血干细胞移植的白血病患者的疗效及相关毒性[J].癌症,2007,26(8):914-918. 被引量:8
  • 4Hugo F Fernandez,Hai T Tran,Federico Albrecht,Shari Lennon,Humberto Caldera,Mark S Goodman.??Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation(J)Biology of Blood and Marrow Transplantation . 2002 (9)
  • 5Borje S Andersson,Ashwin Kashyap,Victor Gian,John R Wingard,Hugo Fernandez,Pablo J Cagnoni,Roy B Jones,Stefano Tarantolo,Wendy W Hu,Karl G Blume,Stephen J Forman,Richard E Champlin.??Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: A phase II study(J)Biology of Blood and Marrow Transplantation . 2002 (3)
  • 6Borje S Andersson,Peter F Thall,Timothy Madden,Daniel Couriel,Xuemei Wang,Hai T Tran,Paolo Anderlini,Marcos de Lima,James Gajewski,Richard E Champlin.??Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: Defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia(J)Biology of Blood and Marrow Transplantation . 2002 (9)
  • 7Borje S. Andersson,Timothy Madden,Hai T. Tran,Wendy W. Hu,Karl G. Blume,Diana S.-L. Chow,Richard E. Champlin,William P. Vaughan.??Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: A phase I study(J)Biology of Blood and Marrow Transplantation . 2000 (5)
  • 8Hoffer Erica,Akria Luiza,Tabak Arek,Scherb Inna,Rowe Jacob M,Krivoy Norberto.A simple approximation for busulfan dose adjustment in adult patients undergoing bone marrow transplantation. Therapeutic Drug Monitoring . 2004
  • 9张耀东.造血干细胞移植中白消安血药浓度监测及其临床意义[J].今日药学,2009,19(7):16-17. 被引量:3
  • 10张善堂,孙自敏,会兰,方焱,耿良权,唐丽琴,吴云,谯川南,屈建.大剂量口服白消安在异基因造血干细胞移植预处理患者体内药动学研究[J].中国药学杂志,2009,44(18):1416-1419. 被引量:4

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部